13.10.2024, 862 Zeichen

Marinomed: Marinomed Biotech AG has published clinical data from the phase II dose-finding clinical trial evaluating the efficacy of Tacrosolv eye drops in patients with allergic rhinoconjunctivitis in the peer-reviewed “Clinical Ophthalmology” journal. The placebo-controlled allergen challenge trial assessed the efficacy and safety of two different doses of Tacrosolv. The results show that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus) significantly reduced ocular symptoms of allergic conjunctivitis, and surprisingly, also the associated nasal allergy symptoms. Remarkably, these results were achieved with a dose that is 20-fold lower than that of the only Tacrolimus eye drop product currently on the market.
Marinomed Biotech: weekly performance: 0.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/10/2024)

Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #135: Rolf Majcen, unser Business Athlete 2016, der auch im Guinness-Buch der Rekorde steht

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, DO&CO, Rosenbauer, Immofinanz, Addiko Bank, CA Immo, VIG, Uniqa, Amag, Zumtobel, AT&S, Polytec Group, Marinomed Biotech, SW Umwelttechnik, Wienerberger, Wolford, Warimpex, EuroTeleSites AG, Porr, Oberbank AG Stamm, Agrana, EVN, Flughafen Wien, OMV, Palfinger, Österreichische Post, RHI Magnesita, S Immo, Telekom Austria, Sartorius, Walt Disney.

---